Paris, 30 June 2016
Scotto & Associés advises Zaka, Pierre Bastid’s family office, on the flotation on Alternext Paris of Pharnext, a biopharmaceutical French company with an advanced range of drugs targeting neurodegenerative diseases.
Pharnext expects the flotation to generate between €36.4m and €48.2m. Subscriptions worth €9m have already been secured by Zaka, Truffle Capital and Ipsen Pharma as its historical shareholders.
The team at Scotto & Associés was Thomas Bourdeaut (partner) and François Bossé-Cohic.